Radioimmunoguided surgery benefits for recurrent colorectal cancer

Schneebaum, Schlomo; Papo, J; Graif, Moshe; Baratz, M; Baron, Jack; Skornik, Yehuda

doi:10.1007/bf02305548

Cited by 29 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of RIGS in second-look colorectal procedures was initially introduced to find occult tumor sites or micrometastases and to provide surgeons with more intraoperative information allowing better staging and surgical decision making (15)(16)(17)(18). In second-look colorectal procedures, initial reports concerned the possibility of finding occult tumor sites and extending the margins of resection in about one-third of patients.…”

Section: Discussionmentioning

confidence: 99%

“…The second step of the survey is then performed in the same areas using a handheld gamma-detecting probe (GDP) (Neoprobe 1000 GDP, Neoprobe Co., Dublin, OH). A direct tissue contact of the GDP is considered the optimal for RIGS survey purposes [15][16][17][18]. Nevertheless, during examination of the liver, because of the possible presence of metastases deep in the parenchyma, RIGS evaluation is always associated with the use of intraoperative ultrasound scan.…”

Section: Methodsmentioning

confidence: 99%

“…Several reports have shown benefits in primary and recurrent colorectal cancer procedures and indicate a potential for RIGS to increase survival rates in these patients [15][16][17][18]. Our study investigates the use of RIGS system in asymptomatic patients with previous surgery for primary colorectal cancer who are candidates for secondlook operations based solely on rising CEA serum levels.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

Bertoglio¹,

Benevento²,

Percivale³

et al. 1998

Semin. Surg. Oncol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

Bertoglio¹,

Benevento²,

Percivale³

et al. 1998

Semin. Surg. Oncol.

View full text Add to dashboard Cite

“…All counted areas were accurately excised to the level of abdominal muscles for histological identification. Positive targeting was determined when 2-s counts were more than twice as high as those of normal adjacent tissue (Schneebaum et al 1997). The localization index (LI) of the tumor, identified as radioactivity of tumor or tumor-bearing peritoneum per g of tissue divided by that of nontumor-bearing peritoneum per g of tissue, was calculated.…”

Section: Metabolism Biodistribution and Tumor Targetingmentioning

confidence: 99%

Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab’)2

Kim

Hong

Lee

et al. 2005

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…[28][29][30] Similarly, scintigraphy with technetium 99m-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody has shown promising preliminary results. 31,32 However, these newer imaging modalities have yet to significantly improve the clinical outcome in patients with metastatic colorectal cancer. The cost, limited availability, and unclear utility of these techniques currently limit their routine use for the detection of recurrent colorectal cancer.…”

Section: Evaluation Of the Patient With Hepatic Metastasesmentioning

confidence: 99%

Management of hepatic metastases

Choti

Bulkley

1999

Liver Transpl

View full text Add to dashboard Cite

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright 1999 by the American Association for the Study of Liver DiseasesA s many as 50% of the patients with a primary malignancy will eventually develop metastases in the liver, a percentage greater than for any other organ, including the lung. Although primary tumors that drain principally into the portal circulation are more likely than others to develop hepatic metastases, many tumors arising in other sites, such as the breast and lung, also commonly develop hepatic metastases. Although the liver represents a common site of spread from many of these solid tumors, isolated hepatic metastases most commonly occur from colorectal and neuroendocrine tumors. Other less common malignancies also can metastasize predominantly to the liver. For most other solid malignancies, the pattern of metastatic disease is most often that of generalized dissemination. Colorectal MetastasesCancer of the colon and rectum is the third most commonly diagnosed cancer in the United States. An estimated 131,600 new cases will have been discovered in 1998, comprising 11% of new cancer diagnoses. 1 An estimated 56,500 deaths will occur from colorectal cancer that year, comprising 10% of all cancer deaths. 1 Although mortality from largebowel cancer has been improving over the past 30 years, largely because of improvements in early detection, diagnosis, and treatment, approximately 50% of the patients with colorectal cancer eventually die of their neoplastic disease. 1 The liver is the most commonly involved organ in patients with metastatic colorectal cancer. Approximately 20% of these patients have clinically recognizable liver metastases at the time of their primary diagnosis. 1,2 After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of the patients will subsequently manifest metastatic liver disease. Given these figures,...

show abstract

Radioimmunoguided surgery benefits for recurrent colorectal cancer

Abstract: RIGS technology offers a substantial benefit for patients undergoing surgery for recurrent colorectal cancer and a better chance of finding recurrent tumor intraoperatively in patients who have elevated CEA levels with no other CT findings.

Cited by 29 publications

References 22 publications

Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

Radioimmunoguided surgery benefits in carcinoembryonic antigen-directed second-look surgery in the asymptomatic patient after curative resection of colorectal cancer

Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab’)2

Management of hepatic metastases

Contact Info

Product

Resources

About